Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2025)

Candel Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $15.6 million in Q4 2025.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $15.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.6 million (changed N/A YoY) and the FY2025 annual result came in at $15.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities retreated to $15.6 million in Q4 2025 per CADL's latest filing, from $15.9 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $27.4 million in Q3 2021 and troughed at $433000.0 in Q3 2023.
• A 5-year average of $9.1 million and a median of $5.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 90.64% in 2023, then soared 3568.82% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $18.3 million in 2021, then plunged by 89.69% to $1.9 million in 2022, then sank by 51.33% to $916000.0 in 2023, then jumped by 1634.28% to $15.9 million in 2024, then dropped by 1.81% to $15.6 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $15.6 million, $15.9 million, and $14.2 million for Q4 2025, Q3 2024, and Q2 2024 respectively.